 Luminex Corporation NASDAQ: LMNX today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG Respiratory Pathogen Panel RPP to include the SARS-CoV-2 virus for high-throughput COVID-19 testing. The new test is a combination of the companys original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and the most relevant circulating pathogen today, SARS-CoV-2. 